These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label Amylin Pharmaceuticals Inc. Eli Lilly and Company BYETTAŽ Exenatide injection NCT00044668 Diabetes Mellitus, Type 2 Phase III http://pi.lilly.com/us/byetta-pi.pdf Clinical Study Summary Protocol Number 2993-117: An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects with Type 2 Diabetes Treated with Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination The contents of this web site should not be interpreted as medical advice, and should not be relied upon as the basis for any decision or action. You should always consult your health care provider for advice on your specific situation. Amylin Pharmaceuticals, Inc. (Amylin Pharmaceuticals) will make good faith efforts to include accurate and up to date information about results from completed clinical trials on the ClinicalStudyResults.org web site; however, because the status of studies often changes, Amylin Pharmaceuticals makes no warranties or representations of any kind as to the currency or completeness of the information contained on the web site. The information provided by Amylin Pharmaceuticals for posting on the ClinicalStudyResults.org web site is for informational purposes only and is not intended to provide or make any claims about the safety or efficacy of any product of Amylin Pharmaceuticals. Persons accessing and using information posted by Amylin Pharmaceuticals on the ClinicalStudyResults.org web site do so at their own risk. Amylin Pharmaceuticals disclaims all warranties, express or implied, including warranties of merchantability or fitness for a particular purpose. Amylin Pharmaceuticals shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Amylin Pharmaceuticals on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. Some of the contents of this web site may link you to other web sites on the Internet. Amylin Pharmaceuticals takes no responsibility for information found on third party web sites outside of its control, and any link to such a third party web site in no way constitutes or implies an endorsement or recommendation by Amylin Pharmaceuticals. Although Amylin Pharmaceuticals attempts to provide links only to third-party web sites that comply with applicable laws and regulations, the contents of these third-party web sites are subject to change without notice to Amylin Pharmaceuticals. Amylin Pharmaceuticals therefore cannot be responsible for, and accepts no liability for, any information or opinion contained on any third-party web site. Company Study 2993-117 Back to Search Results